Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC
Andreea Neblea
International Association for the Study of Lung Cancer Sep 9 2025 A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC). The research, led by scientists at the National Cancer Center of China, assessed ctDNA in 177 patients with LS-SCLC
din zilele anterioare